Characteristic | Number of patients (percent) |
---|---|
Age, yrs | |
≤ 59 | 13 (46.4) |
> 59 | 15 (53.6) |
Primary tumor location | |
Ovary | 26 (92.9) |
Fallopian tube | 2 (7.1) |
Peritoneum | 0 (0) |
International FIGO stage | |
I | 4 (14.3) |
II | 2 (7.1) |
III | 19 (67.9) |
IV | 3 (10.7) |
Histological type | |
Serous | 25 (89.3) |
Endometrioid | 1 (3.6) |
Mixed serous and endometrioid | 1 (3.6) |
Mixed serous and mucious | 1 (3.6) |
Family history of cancer | |
Yes | 10 (35.7) |
No | 15 (53.6) |
Missing data | 3 (10.7) |
ECOG | |
0 | 18 (64.3) |
1 | 10 (35.7) |
BRCA | |
BRCA 1/2 mutation | 11 (39.3) |
Wild type | 11 (39.3) |
Unknown | 6 (21.4) |
Sensitivity to platinum-based chemotherapy | |
Platinum-sensitive | 11 (39.3) |
Platinum-resistant | 13 (46.4) |
Unknown | 4 (14.3) |
Categories of therapy | |
First-line maintenance therapy | 2 (7.1) |
Second-line maintenance therapy | 10 (35.7) |
Treatment after multi-line chemotherapy | 6 (21.4) |
Exploratory therapy | 10 (35.7) |
Primary cytoreductive surgery | |
Yes | 27 (96.4) |
No | 1 (3.6) |
Secondary cytoreductive surgery | |
Yes | 6 (21.4) |
No | 22 (78.6) |
Combination of anti-angiogenic agents | |
Yes | 4 (14.3) |
No | 24 (85.7) |